Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety

The Risk Evaluation and Mitigation Strategy for GlaxoSmithKline’s Avandia (rosiglitazone) includes a prominent role for Takeda’s competing thiazolidinedione Actos (pioglitazone).

More from Archive

More from Pink Sheet